Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII

Diabetes Care

Volumn 28, Issue 3, 2005, Pages 533-538

  Hirsch, Irl B ^a,h   Bode, Bruce W ^b   Garg, Satish ^c   Lane, Wendy S ^d   Sussman, Allen ^e   Hu, Peter ^f   Santiago, Olga M ^f   Kolaczynski, Jerzy W ^g  

^a UNIVERSITY OF WASHINGTON   (United States)

^b ATLANTA DIABETES ASSOCIATES   (United States)

^c B Davis Ctr for Childhood Diabet   (United States)

^d Mountain Diabetes and Endocrine Center   (United States)

^e Rainier Clinical Research Center   (United States)

^f NOVO NORDISK INC   (United States)

^g ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^h UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FRUCTOSAMINE; INSULIN ASPART; INSULIN GLARGINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTINUOUS SUBCUTANEOUS INSULIN INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; GLUCOSE BLOOD LEVEL; GOOD CLINICAL PRACTICE; HUMAN; HYPOGLYCEMIA; INFUSION PUMP; INJECTION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE DAILY INJECTION; RANDOMIZED CONTROLLED TRIAL;

ADULT; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION SCHEDULE; FEMALE; FRUCTOSAMINE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; INSULIN INFUSION SYSTEMS; MALE;

EID: 14644418463     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.28.3.533     Document Type: Article

References (14)

1. Lindholm A, McEwen J, Riis AP: Improved postprandial glycemic control with insulin aspart: a randomized double-blind cross-over trial in type 1 diabetes. Diabetes Care 22:801-805, 1999
2. Anderson JH, Brunelle RL, Koivosto VA, Pfutzner A, Trautmann ME, Vignati L, DiMarchi R, Multicenter Insulin Lispro Study Group: Reduction of postprandial hyperglycemia in IDDM patients on insulin-analog treatment. Diabetes 46:265-270, 1997
3. Raskin P, Klaff L, Bergenstal R, Halle JP, Donley D, Mecca T: A 16-week comparison of the novel insulin analog insulin glargine (HOE901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 23: 1666-1671, 2000
4. Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, Cordoni C, Costa E, Brunetti P, Bolli GP: Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 49:2142-2148, 2000
5. Pickup J, Keen H: Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care 25:593-598, 1996
6. Reynolds RL: Reemergence of insulin pump therapy in the 1990s. South Med J 93:1157-1161, 2000
7. Bode BW, Steed RD, Davidson PC: Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type 1 diabetes. Diabetes Care 19:324-327, 1996
8. Bode BW, Weinstein R, Bell D, McGill J, Nadeau D, Raskin P, Davidson J, Henry R, Huang W-C, Reinhardt RR: Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion. Diabetes Care 25:439-444, 2002
9. Bode BW, Strange P: Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes. Diabetes Care 24:69-72, 2001
10. Tsui E, Barnie A, Ross S, Parkes R, and Zinmann B: Intensive insulin therapy with insulin lispro: a randomized trial of continuous subcutaneous insulin infusion versus multiple daily insulin injection. Diabetes Care 24:1722-1727, 2001
11. Hanaire-Broutin H, MelkiV, Bessières-Lacombe S, Tauber J-P, Study Group for the Development of Pump Therapy in Diabetes: Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment. Diabetes Care 23:1232-1235, 2000
12. DeVries JH, Snoek FJ, Kostense PJ, Masurel N, Heine RJ, the Dutch Insulin Pump Study Group: A randomized trial of continuous subcutaneous insulin infusion and intensive injection therapy in type 1 diabetes for patients with long-standing poor glycemic control. Diabetes Care 25:2074-2080, 2002
13. World Medical Association declaration of Helsinki: recommendations guiding physicians in biomedical research involving human subjects. JAMA 277:925-926, 1997
14. Albright ES, Desmond R, Bell D: Efficacy of conversion from bedtime NPH insulin injection to once- or twice-daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy. Diabetes Care 27:632-633, 2004